Rituximab - CISMeF

Preferred Label : Rituximab;

MeSH definition : A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.;

MeSH synonym : CD20 Antibody, Rituximab; Rituximab CD20 Antibody;

CISMeF synonym : Antibody, Rituximab CD20; IDECC2B8 Antibody; IDECC2B8;

MeSH hyponym : GP2013; mabthera; IDEC-C2B8 antibody; rituxan; IDEC C2B8 Antibody; IDEC-C2B8; IDEC C2B8;

MeSH Related Number : 174722-31-7;

Wikipedia link : https://en.wikipedia.org/wiki/Rituximab;

Is substance : O;

UNII : 4F4X42SYQ6;

Details

Origin ID

D000069283;

UMLS CUI

C0393022;

ATC code(s)
- rituximab [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Ibritumomab Tiuxetan [NCIt concept]
- Murine Monoclonal Antibody 2B8 [NCIt concept]
- rituximab [medical devices type]
CISMeF manual mappings
- Rituximab [NCIt concept]
- Rituximab (substance) [SNOMED CT concept]
Exact mapping(s) to DCI
- rituximab [International Nonproprietary Name]
Pharmacological action(s)
- Antineoplastic Agents, Immunological [MeSH Descriptor]
- antirheumatic agents [MeSH Descriptor]
- immunologic factors [MeSH Descriptor]
Record concept(s)
- GP2013 [MeSH concept]
- IDEC-C2B8 antibody [MeSH concept]
- mabthera [MeSH concept]
- rituxan [MeSH concept]
- rituximab [MeSH concept]
Related MeSH Supplementary Concept(s)
- 131I-rituximab [MeSH Supplementary Concept]
- 177Lu-DOTA-rituximab [MeSH Supplementary Concept]
- 89Zr-rituximab [MeSH Supplementary Concept]
- R-CHOP protocol [MeSH Supplementary Concept]
- R-CVP protocol [MeSH Supplementary Concept]
- R-FCM protocol [MeSH Supplementary Concept]
- rituximab-alliinase conjugate [MeSH Supplementary Concept]
- technetium 99m carbonyl DTPA-rituximab [MeSH Supplementary Concept]
- technetium 99m rituximab [MeSH Supplementary Concept]
- terbium-rituximab [MeSH Supplementary Concept]
- thorium-227-DOTA-rituximab [MeSH Supplementary Concept]
- thorium-4-benzyl-DOTA-rituximab [MeSH Supplementary Concept]
See also
- antigens, CD20 [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing rituximab (medicinal product) [SNOMED CT concept]
- Rituximab [NCIt concept]
- Rituximab (substance) [SNOMED CT concept]
- riTUXimab [LOINC component]
- rituximab [ATC Code]
- rituximab [International Nonproprietary Name]
Validated automatic mappings to BTNT
- rituximab [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients